Another double-blind RCT involved 84 overweight/obese patients with non-alcoholic fatty liver disease (NAFLD), and it was observed that CUR supplementation (two 40 mg capsules/day after meals for 3 months) caused a reduction in proinflammatory markers, such as TNFα, hs-CRP, and IL-6 (p < 0.05), as well as significant positive changes in many biochemical (i.a. lipid profile and glucose indices) and anthropometric parameters (waist circumference) [133]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.